UCLA researchers from the Department of Psychiatry has created a novel cell-based seeding assay for sensitive, specific and high throughput detection of mutant Huntingtin proteins in biological samples.
BACKGROUND: Huntington’s disease (HD) is a lethal genetic disorder that is caused by mutations in the huntingtin protein (mHTT). Genetic errors cause an elongated repeat motif to result in a polyglutamine (polyQ) stretch in the expressed protein, causing it to form aggregates. These aggregates accumulate in the nerve cells eventually lead to their breakdown, incurring debilitating effects. Current molecular methods of diagnosing HD include direct detection, in vitro aggregation detection and cell based detection. Direct detection of HTT uses antibodies, which can only detect a subset of HTT in soluble, monomer forms. In vitro aggregation detection lacks sensitivity. Other existing cell based detection approaches are prone to false positives and are labor intensive.
INNOVATION: A novel high throughput cell-based seeding assay was developed to detect mutant HTT proteins. This approach utilizes a transgenic cell line that expresses a form of mHTT, which is linked to a green fluorescent protein (GFP), making any aggregates easily quantifiable. The cell line has a very low baseline level of aggregates. However, it can be highly specifically induced to form aggregates with even very small aggregate seeds are introduced from HD patients or mouse samples. The readout correlates well with the amount of seeds added and with the disease stage of the HD patients.
APPLICATIONS
Huntington's Disease diagnosis
- Drug discovery
- Clinical trial biomarker
ADVANTAGES
- Specific
- Sensitive
- High throughput
- Correlates with disease progression
- Compatible with biological samples